Citation:Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, et al 2012

Citation

Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012 Nov;62(5):745-52 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22704366.

This is a publication of ERSPC

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, et al 2012	For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?	Tracy Tsang	completed
Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, et al 2012 2	For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?	Suzanne Hughes	completed

Compare quality appraisals for each clinical question

• [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?|]] (compare critical appraisals)
• [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?|]] (compare critical appraisals)

Cited by

1. ERSPC
2. Introduction
3. PSA Testing strategies